SCHEMBL2178229

SCHEMBL2178229

CNc1ccc(S(=O)(=O)Nc2nnc(C)s2)cc1

nearest known ligand 0.71

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.71
LMNA P02545 1/20 0.71
PKM P14618 4/20 0.68
HPGD P15428 1/20 0.68
AKT1 P31749 5/20 0.64
CA1 P00915 3/20 0.52
CA2 P00918 3/20 0.52
CASP6 P55212 1/20 0.52
CTDSP1 Q9GZU7 1/20 0.52
CA9 Q16790 2/20 0.51
CA12 O43570 1/20 0.51
PIK3CA P42336 1/20 0.50
CCNT1 O60563 1/20 0.50
CDK9 P50750 1/20 0.50
RECQL P46063 1/20 0.49
HSD17B10 Q99714 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11893082 0.86 ALDH1A1 (0.77) ALDH1A1LMNAPKMHPGDAKT1
SCHEMBL14864420 0.84 ALDH1A1 (0.66) ALDH1A1LMNAPKMHPGDAKT1
SCHEMBL2196247 0.84 AKT1 (0.64) ALDH1A1LMNAPKMHPGDAKT1
Sulfamethizole SCHEMBL26453 0.83 ALDH1A1 (1.00) ALDH1A1LMNAPKMHPGDAKT1
SCHEMBL2176360 0.83 ALDH1A1 (0.73) ALDH1A1LMNAPKMHPGDAKT1
SCHEMBL286629 0.83 ALDH1A1 (0.71) ALDH1A1LMNAPKMHPGDAKT1
SCHEMBL1094305 0.83 ALDH1A1 (0.72) ALDH1A1LMNAPKMHPGDAKT1
Sulfamethizole SCHEMBL1566142 0.82 ALDH1A1 (0.97) ALDH1A1LMNAPKMHPGDAKT1
SCHEMBL2178178 0.81 PKM (0.74) ALDH1A1LMNAPKMHPGDAKT1
SCHEMBL11891715 0.81 ALDH1A1 (0.69) ALDH1A1LMNAPKMHPGDAKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130022629-A1 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2013-01-24 US disclosed
US-20130022629-A1 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2013-01-24 US disclosed
WO-2011082400-A2 MODULATORS OF IMMUNOINHIBITORY RECEPTOR PD-1, AND METHODS OF USE THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-07-07 WO disclosed
WO-2011082400-A2 MODULATORS OF IMMUNOINHIBITORY RECEPTOR PD-1, AND METHODS OF USE THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130022629-A1 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof CD274, PDCD1LG2, PDCD1 ALDH1A1 380/4885LMNA 4797/4885PKM 2285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.